Jump to ContentJump to Main Navigation
Show Summary Details
Weitere Optionen …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2018: 156.09

Open Access
Alle Formate und Preise
Weitere Optionen …
Band 9, Heft 2


Volume 10 (2015)

Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?

Jacopo Giuliani / Marina Marzola
Online erschienen: 13.02.2014 | DOI: https://doi.org/10.2478/s11536-013-0154-9
  • [1] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300 http://dx.doi.org/10.3322/caac.20073CrossrefGoogle Scholar

  • [2] Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944 http://dx.doi.org/10.1056/NEJMoa032646CrossrefGoogle Scholar

  • [3] Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist. 2005;10:215–224 http://dx.doi.org/10.1634/theoncologist.10-3-215CrossrefGoogle Scholar

  • [4] Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098 http://dx.doi.org/10.1056/NEJMoa031317CrossrefGoogle Scholar

  • [5] Licitra L, Felip E; ESMO Guidelines Working Group. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:121–122 http://dx.doi.org/10.1093/annonc/mdp149CrossrefGoogle Scholar

  • [6] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–28 http://dx.doi.org/10.1016/S1470-2045(09)70311-0CrossrefGoogle Scholar

  • [7] Frampton JE. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs. 2010;70:1987–2010 http://dx.doi.org/10.2165/11205010-000000000-00000CrossrefGoogle Scholar

  • [8] Forastiere AA. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol. 2008;97:701–707 http://dx.doi.org/10.1002/jso.21012CrossrefGoogle Scholar

  • [9] Pignon JP, le Maítre A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACHNC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14 http://dx.doi.org/10.1016/j.radonc.2009.04.014CrossrefGoogle Scholar

  • [10] Levy AR, Johnston KM, Sambrook J, et al. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr Med Res Opin 2011;27:2253–2259 http://dx.doi.org/10.1185/03007995.2011.633989CrossrefWeb of ScienceGoogle Scholar

  • [11] Vermorken JB, Mesia R, Rivera F, et al. Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–1127 http://dx.doi.org/10.1056/NEJMoa0802656CrossrefGoogle Scholar

  • [12] Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171–2177 http://dx.doi.org/10.1200/JCO.2006.06.7447CrossrefGoogle Scholar

  • [13] Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072–1078 http://dx.doi.org/10.1200/JCO.2004.00.1792CrossrefGoogle Scholar

  • [14] Kabolizadeh P, Kubicek GJ, Heron DE, Ferris RL, Gibson MK. The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther 2012;12:517–528 http://dx.doi.org/10.1517/14712598.2012.667397Web of ScienceCrossrefGoogle Scholar


Online erschienen: 13.02.2014

Erschienen im Druck: 01.04.2014

Quellenangabe: Open Medicine, Band 9, Heft 2, Seiten 279–284, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-013-0154-9.

Zitat exportieren

© 2014 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Kommentare (0)